Drug Profile
PAN 811
Alternative Names: PAN-811Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Panacea Pharmaceuticals
- Class Antidementias; Cytoprotectives; Neuroprotectants; Pyridines; Small molecules; Thiosemicarbazones
- Mechanism of Action Antioxidants; Chelating agents; Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease; Stroke
Most Recent Events
- 16 May 2018 Panacea Pharmaceuticals is now called Sensei Biotherapeutics
- 07 Nov 2007 Pharmacodynamics data presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) ,
- 21 Jul 2006 Data presented at the 10th International conference on Alzeimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's disease pharmacodynamics section